Resources Repository
-
ReviewPublication 2016Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases …
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases (NCDs) on development and economic growth in the countries of Latin America and the Caribbean (LAC). This collection of manuscripts examines the complex interplay among NCDs, health expenditures and financial investments in health, poverty, and inequities, using up-to-date information and evidence from the LAC region. There is compelling proof that NCDs are a major and growing problem for low- and…
Technology Assessment | Cost-Effectiveness Analysis | Costing Methods | Health/Medicine | Policy/Regulation | Chronic Disease/Risk | Priority Setting/Ethics | Child/Nutrition | Mental Health | Social Determinants | Health Systems | Economics/Finance | Food/Agriculture | Latin America & Caribbean -
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Evidence Synthesis | Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Health/Medicine | Policy/Regulation | Decision Analysis | Benefit-Cost Analysis | Global | Graduate | Doctoral | Professional -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Technology Assessment | Cost-Effectiveness Analysis | Health/Medicine | Policy/Regulation | Chronic Disease/Risk | Priority Setting/Ethics | Infectious Diseases | Child/Nutrition | Health Systems | Economics/Finance | Government/Law | North America -
ReviewPublication 2018Primary & Secondary Prevention Interventions for Cardiovascular Disease in LMIC's
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for …
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for the money, the authors conducted a systematic review, including 50 studies. Included studies were those that reported full economic evaluations of individual and population-based interventions (pharmacologic and non-pharmacologic), for primary and secondary prevention of CVD among adults in LMIC. The majority of the studies were of modelled evaluations, with significant heterogeneity in methods. Most of the economic evaluations evaluated were…
Evidence Synthesis | Costing Methods | Health Outcomes | Health/Medicine | Chronic Disease/Risk | Global -
ReviewPublication 2023Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: Methodological Review
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms …
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms in Parkinson’s disease in studies published post-2010. Methods included a systematic literature search using databases such as PubMed, EconLit, Cochrane, and several UK National Health Service databases, covering March 2010 to July 2022. The quality of the identified studies was assessed using a checklist from the German Scientific Working Group. Results showed that 20 studies were evaluated, most employing Markov…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk -
ReviewPublication 2023Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: Systematic Review
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) …
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) in at-risk adult populations. Methods included searching PubMed and Scopus for articles published between January 2016 and May 2022. The first reviewer screened all articles, while a second reviewer independently validated a random 10% sample. Discrepancies were resolved through discussion, with a third reviewer involved if necessary. Costs were standardized to 2021 euros. Reporting quality was evaluated using the CHEERS…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk -
ReviewPublication 2023Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic …
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic drugs (NIADs) within glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors for treating type 2 diabetes mellitus (T2DM). The study focused on economic results and underlying methodological choices. Methods included searching PubMed, Embase, and Econlit databases from January 1, 2018, to November 15, 2022. Two reviewers screened titles, abstracts, and full texts for relevance…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Mathematical Models | Europe -
ReviewPublication 2023Economic & Humanistic Burden of Osteoarthritis: Systematic Review of Large Sample Studies
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported …
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported by large sample studies since 2016. Medline (via Ovid) and Embase were searched using an updated strategy based on a previous review. Studies with a sample size ≥1000 that measured direct or indirect costs or health-related quality of life (HRQL) of OA were included. Pairs of reviewers independently screened studies, and an arbitrator resolved discrepancies. The Kappa value for agreement…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Preferences/Values | Global -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Evidence Synthesis | Technology Assessment | Health/Medicine | Policy/Regulation | Preferences/Values